Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072434 · ClinicalTrials.gov registry record · Phase 3
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,199
- Enrollment target
NCT02072434: Completed Phase 3 study, sponsored by Daiichi Sankyo.
NCT02072434 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 2,199 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (185% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02072434, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,199 participants
- Enrollment target
Study Summary
The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It will see if edoxaban prevents stroke and other blood clotting problems as well and as safely as warfarin. People with atrial fibrillation (irregular heartbeat) might be able to join. Their doctors must plan to use shock to make their hearts beat normally. About 2200 people from different countries will join. They will have an equal chance of receiving either treatment. They are anticipated to be in the study for around 82 days. Tests will include physicals and finger-pricks. Participants will provide blood and urine samples.
Interventions
- DRUG Enoxaparin
- DRUG Warfarin
- DRUG Edoxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,199 participants |
| Start Date | 2014-03-25 |
| Est. Completion | 2016-02-03 |
| Phase | Phase 3 |
What the finished NCT02072434 record still lists
NCT02072434 is an interventional study that assigns participants to a tested intervention. Its 2,199 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (185% higher).
The record links to 0 conditions, and to 3 interventions - of which Enoxaparin is the first listed.
NCT02072434 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02072434 about?
NCT02072434 is a clinical study titled "Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)". The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It will see if edoxaban prevents stroke and other blood clotting problems as well and as safely as warfarin. People with atrial fibrillation (irregular heartbeat) might be able to join. Their doctors must plan...
What is the current status of trial NCT02072434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,199 participants. The study started on 2014-03-25. Estimated completion is 2016-02-03.
What interventions are being tested in trial NCT02072434?
The interventions under investigation include: Enoxaparin (DRUG), Warfarin (DRUG), Edoxaban (DRUG).
Who is sponsoring clinical trial NCT02072434?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02072434's enrollment target sits among peer trials
2,199 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI